Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: The objective of this analysis was to assess the frequency of treatment optimization in cases where treatment target was not achieved, and to describe the type of changes made in RA patients initiating treatment with infliximab or golimumab in Canadian routine clinical care.
Methods: BioTRAC is an ongoing, prospective registry of patients initiating treatment for RA, ankylosing spondylitis, or psoriatic arthritis with infliximab, golimumab or ustekinumab. RA patients enrolled during 2002-2014 and with available CDAI information at both months 6 and 12 were included. DA was defined according to the CDAI criteria (remission: ≤2.8; low: >2.8 to ≤10; moderate: >10 to ≤22; high: >22). The association between treatment changes and target achievement was assessed with the Chi-square test.
Results: A total of 498 patients were included, with a mean (SD) age and disease duration of 56.4 (13.2) and 8.6 (8.6) years, respectively. The majority of patients were female (74.1%) and treated with infliximab (74.5%).
Conclusion: These results suggest that a considerable portion of patients on biologics are not treated to a CRA recommended target in Canada. Treatment adjustment was found to be mainly associated with the physician’s global assessment of disease activity and resulted in better outcomes. PtGA and TJC28 were also significantly higher in those receiving treatment adjustments, while SJC did not correlate with treatment adjustments. The reasons for lack of treatment adjustment in patients not at DA target levels should be further explored.
To cite this abstract in AMA style:Baer P, Chow A, Starr M, Haraoui B, Arendse R, Teo M, Rampakakis E, Psaradellis E, Lehman AJ, Nantel F, Osborne B, Tkaczyk C, Maslova K. Do Canadian Rheumatologists Actually Treat to Target Once a Biologic Has Been Initiated? an Analysis from a Prospective, Observational Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/do-canadian-rheumatologists-actually-treat-to-target-once-a-biologic-has-been-initiated-an-analysis-from-a-prospective-observational-registry/. Accessed January 15, 2021.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-canadian-rheumatologists-actually-treat-to-target-once-a-biologic-has-been-initiated-an-analysis-from-a-prospective-observational-registry/